Incyte (INCY) and MorphoSys (MOR) Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab in Combination with Lenalidomide

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Incyte (INCY) and MorphoSys (MOR) Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab in Combination with Lenalidomide

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse

December 11, 2021 12:00 PM EST

RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies Results from the retrospective cohort analysis indicate significant overall survival improvement compared with Pola-BR and R2

BOSTON & WILMINGTON, Del.--(BUSINESS WIRE)-- MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (NASDAQ: INCY) today announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi®) in combination with lenalidomide against the most frequently used... More